Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) are increasingly used in clinical settings, research and drug trials. However, their broad-scale use on different technology platforms is hampered by the lack of standardization at the level of sample handling, determination of concentrations of analytes and the absence of well-defined performance criteria for in vitro diagnostic or companion diagnostic assays, which influences the apparent concentration of the analytes measured and the subsequent interpretation of the data. There is a need for harmonization of CSF AD biomarker assays that can reliably, across centers, quantitate CSF biomarkers with high analytical precision, selectivity and stability over long time periods. In this position paper, we discuss reference procedures for the measurement of CSF AD biomarkers, especially amyloid β42 and tau. We describe possible technical approaches, focusing on a selected reaction monitoring mass spectrometry assay as a candidate reference method for quantification of CSF amyloid β42.

[1]  L. Shaw,et al.  Analytical aspects of molecular Alzheimer's disease biomarkers. , 2012, Biomarkers in medicine.

[2]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[3]  J Schröder,et al.  Age and diagnostic performance of Alzheimer disease CSF biomarkers , 2012, Neurology.

[4]  Manfred Rauh,et al.  LC-MS/MS for protein and peptide quantification in clinical chemistry. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[6]  Leslie M. Shaw,et al.  Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2012, Alzheimer's & Dementia.

[7]  Erin E. Chambers,et al.  Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.

[8]  W. Xu,et al.  Association Study of Clusterin Polymorphism rs11136000 With Late Onset Alzheimer’s Disease in Chinese Han Population , 2011, American journal of Alzheimer's disease and other dementias.

[9]  K. Blennow,et al.  Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment. , 2011, Current pharmaceutical design.

[10]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[11]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[12]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[13]  I. Zegers,et al.  Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. , 2010, Clinical chemistry.

[14]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[15]  I. Zegers,et al.  Standardizing plasma protein measurements worldwide: a challenging enterprise , 2010, Clinical chemistry and laboratory medicine.

[16]  M. Blankenstein,et al.  Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop , 2010, International journal of Alzheimer's disease.

[17]  K. Blennow,et al.  Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid , 2010, International journal of Alzheimer's disease.

[18]  J. Henny,et al.  Traceability of values for catalytic activity concentration of enzymes: a Certified Reference Material for aspartate transaminase , 2010, Clinical chemistry and laboratory medicine.

[19]  K. Blennow,et al.  Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall , 2010, Clinical chemistry and laboratory medicine.

[20]  Gerhard Schumann,et al.  Standardization in clinical enzymology: a challenge for the theory of metrological traceability , 2010, Clinical chemistry and laboratory medicine.

[21]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[22]  E. Kilpatrick,et al.  Reference measurement procedure development for C-reactive protein in human serum. , 2009, Analytical chemistry.

[23]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[24]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[25]  Michael P. Cusack,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[26]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[27]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[28]  Mauro Panteghini,et al.  Traceability as a unique tool to improve standardization in laboratory medicine. , 2009, Clinical biochemistry.

[29]  W. Burkitt,et al.  Toward Système International d'Unité-traceable protein quantification: from amino acids to proteins. , 2008, Analytical biochemistry.

[30]  T. Lanz,et al.  Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Aβ quantification following passive immunization with Aβ antibodies , 2008, Journal of Neuroscience Methods.

[31]  Henrik Zetterberg,et al.  Characterization of tau in cerebrospinal fluid using mass spectrometry. , 2008, Journal of proteome research.

[32]  R. Little,et al.  The IFCC Reference Measurement System for HbA1c: a 6-year progress report. , 2008, Clinical chemistry.

[33]  Kit-Yi Leung,et al.  Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis* , 2007, Journal of Biological Chemistry.

[34]  M. Welch,et al.  Development and evaluation of a candidate reference measurement procedure for the determination of testosterone in human serum using isotope dilution liquid chromatography/tandem mass spectrometry , 2007, Analytical and bioanalytical chemistry.

[35]  D. Holtzman,et al.  Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[36]  P. Lewczuk,et al.  International quality control survey of neurochemical dementia diagnostics , 2006, Neuroscience Letters.

[37]  M. Panteghini,et al.  The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) , 2006, Clinical chemistry and laboratory medicine.

[38]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[39]  Hedvig Perlmann,et al.  Enzyme-Linked Immunosorbent Assay , 2006 .

[40]  R. Paroni,et al.  Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood , 2002, Clinical chemistry and laboratory medicine.

[41]  A. M. Johnson,et al.  Protein Standardization IV: Value Transfer. Procedure for the Assignment of Serum Protein Values from a Reference Preparation to a Target Material , 2001, Clinical chemistry and laboratory medicine.

[42]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[43]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[44]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Glenner,et al.  Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[48]  Sean D Sullivan,et al.  Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[49]  K. Blennow,et al.  High education may offer protection against tauopathy in patients with mild cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[50]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.